Skip to main content

Page last checked

Research compound · not FDA-approved

Macupatide

Also called LY3532226.

Macupatide is an experimental weekly shot that acts on the GIP receptor, not GLP-1.

What matters first

Why people look it up
Researchers are studying it in people with type 2 diabetes and in separate obesity trials.
What the evidence shows
A study in people with type 2 diabetes found improved insulin sensitivity. The obesity study registries do not post results. Macupatide is not FDA approved.
Dose status
Macupatide is not FDA-approved, so no dosing label exists for it. The sections below explain what researchers tested and what remains unknown.

Evidence snapshot

Published human trial

The fastest way to see what kind of evidence this page is built on.

Regulation
Not FDA-approvedNo US prescribing label
Dose source
Human study2 reported dose rows
Safety evidence
No listed safety findingsNo reactions reported here
Sources
8 cited sourcesMedical review complete · 2026-09-07
Open the shareable evidence image
Macupatide at a glance: published human trial, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.

Further down: research and dosing details · how good the evidence is · questions

Medically reviewed by Kenneth Montecillo, MD2026-09-07open the primary sources

What is known about Macupatide

Macupatide is an experimental weekly shot that acts on the GIP receptor, not GLP-1. A 12-week study in 90 people with type 2 diabetes found improved insulin sensitivity. The study also measured body weight, but it was not a weight-management trial. Separate obesity studies are underway, and their registries do not post results. Macupatide is not FDA-approved.

Macupatide research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
TopicValue
Strongest sourceHuman trial
FDA approvalNot FDA-approved
Studied dosing7.5–20 mg once weekly for 12 weeks in Phase 1b; dulaglutide was added from week 9 in this safety part — from clinical trials
Studied dosing20 mg once weekly for 12 weeks in the Phase 1b insulin-sensitivity comparison — from clinical trials
PresentationMacupatide has no approved vial or mixing instructions; its studies use prepared research injections.

Every row links back to a source listed below. These facts are for reference, not a personal recommendation.

What the evidence for Macupatide is

These numbers come from a study in people that was published in a peer-reviewed journal. The drug or dose may still be experimental and may not have FDA approval.

Human trial
What it establishes
The study gave known doses to a defined group, monitored what happened and compared the results with another group.
What it does not establish
One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.

Read each result with the study length, dose and number of participants. Results from separate trials are not a direct comparison because the people and study designs differ.

Where Macupatide is in clinical trials

8 registered studies; the program has reached phase 2, and 3 are still enrolling.

The soonest a running study expects to finish measuring people is March 2027. That is when the sponsor expects to finish collecting the main measurement. It is not a results date, and not a date anything goes on sale.

  • Phase 2Recruiting

    A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    Eli Lilly and Company · Overweight, Obesity · 400 participants planned · started May 2026

    Main measurement due September 2027 (sponsor estimate)

    NCT07589608 on ClinicalTrials.gov

  • Phase 2Recruiting

    A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

    Eli Lilly and Company · Obesity, Overweight · 200 participants planned · started October 2025

    Main measurement due March 2027 (sponsor estimate)

    NCT07215559 on ClinicalTrials.gov

  • Phase 2Recruiting

    A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

    Eli Lilly and Company · Obesity, Overweight · 1,481 participants planned · started November 2023

    Main measurement due September 2027 (sponsor estimate)

    NCT06143956 on ClinicalTrials.gov

A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.

ClinicalTrials.gov · retrieved 2026-09-07

Every compound we track, and what stage each one has reached →

Regulatory status

Macupatide is investigational.

It has no approved product, prescribing schedule, retail price or availability date. The amounts below belong to a monitored Phase 1 study and are not instructions for personal use.

Full regulatory tracker →

Where to go next on Macupatide

The generic calculator behind the macupatide one

Vial strength and water volume in and the exact mark out, with macupatide as context

Every dosing schedule, including macupatide

7 pages carry trial arms — which is a different object from a chart, with macupatide as context

What is still being tested, including macupatide

2480 registered studies across 34 compounds, read on 2026-09-07, with macupatide as one example

What the FDA has published on macupatide

What has been decided, and what has only been proposed, including Macupatide

Every compound guide, macupatide and the rest

Class, approval status and strongest available source for every compound, with macupatide as one example

Why these macupatide sources were chosen

How an FDA label differs from a human trial or a claim with no human data, with macupatide as one example

Safety notes

  • The peer-reviewed Phase 1b study named reactions at the injection site and diarrhea as the most frequent adverse events
  • Study discontinuations due to treatment-emergent adverse events were uncommon, and the study reported no deaths
  • The selected published findings are not a complete side-effect profile
  • No FDA-approved product, prescribing schedule, price or availability date exists

Questions about Macupatide

Is Macupatide FDA-approved?

No. There is no prescribing label for it, so no approved dose exists — the regulatory status section above has the detail.

How is Macupatide taken?

By injection under the skin, once a week.

How does Macupatide differ from the other compounds in this class?

Macupatide has been studied in people, but it works through a different system from GLP-1 and amylin drugs. Its doses and results are not directly comparable with theirs.

What is not known about Macupatide?

One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.

8primary sources, each with the day we read it — open the documents used on this page